|
Name |
(7Z,9R,11Z,16R,19S)-19-(1H-indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-7,11-diene-2,5,6,21-tetrone
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(7Z,9R,11Z,16R,19S)-19-(1H-indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-7,11-diene-2,5,6,21-tetrone
|
|
SMILES |
C[C@@H]/1C/C=C\C2C3[C@](O3)(C(C4C2(C(=O)CCC(=O)C(=O)/C(=C1)/C)C(=O)N[C@H]4CC5=CNC6=CC=CC=C65)C)C
|
|
InChI |
InChI=1S/C32H36N2O5/c1-17-8-7-10-22-29-31(4,39-29)19(3)27-24(15-20-16-33-23-11-6-5-9-21(20)23)34-30(38)32(22,27)26(36)13-12-25(35)28(37)18(2)14-17/h5-7,9-11,14,16-17,19,22,24,27,29,33H,8,12-13,15H2,1-4H3,(H,34,38)/b10-7-,18-14-/t17-,19?,22?,24+,27?,29?,31-,32?/m1/s1
|
|
InChIKey |
RIZAHVBYKWUPHQ-ZQBBTYACSA-N
|
|
Synonyms |
chaetoglobosin C; 50645-76-6
|
|
CAS | NA | |
PubChem CID | 164182073 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.7 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 109.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 39 | QED Weighted: | 0.251 |
Caco-2 Permeability: | -4.781 | MDCK Permeability: | 0.00003910 |
Pgp-inhibitor: | 0.976 | Pgp-substrate: | 0.035 |
Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.496 |
30% Bioavailability (F30%): | 0.046 |
Blood-Brain-Barrier Penetration (BBB): | 0.532 | Plasma Protein Binding (PPB): | 96.18% |
Volume Distribution (VD): | 0.704 | Fu: | 1.95% |
CYP1A2-inhibitor: | 0.036 | CYP1A2-substrate: | 0.772 |
CYP2C19-inhibitor: | 0.697 | CYP2C19-substrate: | 0.677 |
CYP2C9-inhibitor: | 0.535 | CYP2C9-substrate: | 0.536 |
CYP2D6-inhibitor: | 0.196 | CYP2D6-substrate: | 0.69 |
CYP3A4-inhibitor: | 0.945 | CYP3A4-substrate: | 0.638 |
Clearance (CL): | 10.503 | Half-life (T1/2): | 0.349 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.625 |
Drug-inuced Liver Injury (DILI): | 0.534 | AMES Toxicity: | 0.127 |
Rat Oral Acute Toxicity: | 0.889 | Maximum Recommended Daily Dose: | 0.873 |
Skin Sensitization: | 0.144 | Carcinogencity: | 0.254 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.966 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004470 | 0.817 | D01TSI | 0.268 | ||||
ENC003586 | 0.817 | D0V3ZA | 0.261 | ||||
ENC002442 | 0.779 | D0SP3D | 0.260 | ||||
ENC002646 | 0.748 | D02DMQ | 0.255 | ||||
ENC002441 | 0.722 | D09NNH | 0.254 | ||||
ENC002680 | 0.717 | D0W7WC | 0.247 | ||||
ENC004473 | 0.703 | D09ZIO | 0.247 | ||||
ENC002166 | 0.690 | D05MQK | 0.237 | ||||
ENC002681 | 0.644 | D00YLW | 0.234 | ||||
ENC004447 | 0.644 | D0BV3J | 0.231 |